Mingqian Feng

Title: The Innovative Contributions of Mingqian Feng

Introduction

Mingqian Feng is a prominent inventor based in Rockville, MD (US), known for his significant contributions to the field of biomedical research. He holds a total of 4 patents, showcasing his dedication to advancing medical science and technology.

Latest Patents

One of his latest patents involves the development of human monoclonal antibodies specific for glypican-3 (GPC3) and their applications. This patent describes the identification of antibodies that bind to GPC3 or heparan sulfate (HS) chains on GPC3 with high affinity. These antibodies have demonstrated the capability to inhibit hepatocellular carcinoma (HCC) cell growth and migration. The patent also includes various immunoglobulin molecules, such as IgG antibodies, and antibody fragments, including single-domain VH antibodies and single-chain variable fragments (scFv). Additionally, it provides compositions that incorporate these antibodies, nucleic acid molecules encoding them, expression vectors, and isolated host cells that express the nucleic acids. Furthermore, methods for treating cancer, inhibiting tumor growth or metastasis, and detecting cancer in subjects are also outlined in this patent.

Career Highlights

Mingqian Feng is currently affiliated with the National Institutes of Health, a component of the US Department of Health & Human Services. His work at this esteemed institution has allowed him to contribute to groundbreaking research in cancer treatment and diagnostics.

Collaborations

He has collaborated with notable colleagues, including Mitchell Ho and Dimiter Stanchev Dimitrov, further enhancing the impact of his research through teamwork and shared expertise.

Conclusion

Mingqian Feng's innovative work in developing monoclonal antibodies for cancer treatment exemplifies his commitment to improving healthcare outcomes. His contributions continue to influence the field of biomedical research significantly.